MONTREAL, QUEBEC -- (MARKET WIRE) -- November 08, 2006 -- Ecopia BioSciences Inc. (TSX: EIA) is pleased to announce it will present two scientific posters at the 18th EORTC-NCI-AACR Meeting, held in Prague. The data presented support the unique mechanism of action of ECO-4601 as well as its strong safety profile. ECO-4601, the Company’s lead anticancer drug candidate now in a Phase I clinical trial, has a dual mechanism of action. Not only does the compound inhibit the RAS-mitogen-activated protein kinase (MAPK) pathway at a strategic point, it also selectively binds to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in many cancer cells. This dual activity positions the compound as a uniquely targeted anticancer drug candidate that is now being tested in a Phase I clinical trial involving patients with refractory solid tumors, including pancreatic cancer and glioblastoma.
